Our team

Dr. Pierre Eftekhari

President & Chief Scientific Officer (CSO)

Dr Eftekhari is a life sciences entrepreneur with extensive world-class knowledge in drug development. He has more than fifteen years combined academic and industrial experience in pharmacology. His considerable experience in the drug development process has equipped him to develop state-of-the-art technologies.

Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he has built with pharmaceutical companies and academic laboratories at the international level have given him an in-depth understanding of the pharmaceutical industry’s needs.

He holds a PhD in biology, with a major in pharmacology, from the Louis Pasteur University, Strasbourg.

Léone ATAYI

Chief Financial Officer (CFO)

Leone has been patiently involved in structuring and building up innovative companies for the passed 15 years. She has put her academic knowledge in human resource management and her practical experiences in finance and strategy making at the service of multiple companies. Before joining Inoviem scientific Leone has been working with Polyplus transfection where she acted as CFO.

Dr. Daniel da Costa

Head of Business development

Dr. Da Costa joined Inoviem in 2013. He is an experienced international research project manager, having worked in Glasgow, Portsmouth and Montreal. He has served as project manager for Semia, an innovative business incubator, and Medeuronet, a company dedicated to offering innovative services to the medtech industry.

Dr. da Costa graduated from the Ecole Normale Supérieure in Lyon and holds a PhD in molecular biology and a Master’s in innovation management from the University of Strasbourg.

Dr. Angélique Quartier

Head of biology and molecular pharmacology

Dr. Judith Eschbach

Head of in vivo pharmacology

Camille Torlotin

Assay development manager

Francois Louis

R&D scientist/ regulatory and quality manager

Justine Schneider

Head of proteomics and analytical chemistry

Pierre-Emile Rudolf

AI development and application manager

Scientific Board

Dr. Johan Hoebeke

Retired CNRS Research Director

Dr. Johan Hoebeke has more than 250 publications to his name in peer-reviewed international journals, as well as eight patents. His research interests focus on physical chemistry as applied to molecular immunology and molecular pharmacology. Recently retired from his position as CNRS Research Director in the Department of Immunological and Chemical Therapeutics at the Institute of Molecular and Cell Biology at the University of Strasbourg (France), Dr. Hoebeke began his career teaching at the University of Kinshasa, Democratic Republic of the Congo. Later, he joined the research laboratories at Janssen Pharmaceutical in Belgium. On his return to academic research, he worked as Senior Scientist in the Pathological Biochemistry Department of the Free University of Brussels, Belgium. He also worked at the Jacques Monod Institute in Paris and then at the François Rabelais University in Tours. He spent a sabbatical period in the Wallenberg Laboratories at the University of Gothenburg, Sweden.

Dr. Hoebeke graduated with a BSc (1959) and PhD (1965) in biochemistry from the Catholic University of Leuven, Belgium.

Professor Jörg Wischhusen

Head of the Experimental Tumor Immunology Department of Würzburg University’s Medical School

Since 2013, Prof. Wishchusen has served as Head of the Experimental Tumor Immunology Department of Würzburg University’s Medical School. Currently, his research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance. Strategies to relieve local suppression of NK and T cell effector functions by cytokines and other soluble factors are being investigated for their potential therapeutic use. Prof. Wischhusen trained as a biochemist at the University of Tübingen. After graduating in the field of molecular neuro-oncology, he became Research Group Leader at the Interdisciplinary Centre for Clinical Research in Würzburg, where he focused on mechanisms of tumor progression and immune escape.

Supervisory Board & Investors

Dr. Pierre Eftekhari

President & Chief Scientific Officer (CSO)

Dr Eftekhari is a life sciences entrepreneur with extensive world-class knowledge in drug development. He has more than fifteen years combined academic and industrial experience in pharmacology. His considerable experience in the drug development process has equipped him to develop state-of-the-art technologies.

Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he has built with pharmaceutical companies and academic laboratories at the international level have given him an in-depth understanding of the pharmaceutical industry’s needs.

He holds a PhD in biology, with a major in pharmacology, from the Louis Pasteur University, Strasbourg.

Léone ATAYI

Chief Financial Officer (CFO)

Leone has been patiently involved in structuring and building up innovative companies for the passed 15 years. She has put her academic knowledge in human resource management and her practical experiences in finance and strategy making at the service of multiple companies. Before joining Inoviem scientific Leone has been working with Polyplus transfection where she acted as CFO.

Dr. Daniel da Costa

Head of Business development

Dr. Da Costa joined Inoviem in 2013. He is an experienced international research project manager, having worked in Glasgow, Portsmouth and Montreal. He has served as project manager for Semia, an innovative business incubator, and Medeuronet, a company dedicated to offering innovative services to the medtech industry.

Dr. da Costa graduated from the Ecole Normale Supérieure in Lyon and holds a PhD in molecular biology and a Master’s in innovation management from the University of Strasbourg.

Jean-Paul Ansel

Board Member

Jean-Paul has more than 45 years of international banking and financing experience. His academic knowledge is rooted in Paris business school (ESCP) that allows him to grow his highly riche international experience through  Scoa, Davum, MITSUI, Bank worms group, The Chase Manhattan bank N.A, Merill Lynch, HSBC Investment Bank, Commerzbank securities and Pennel Industries.

Jean-Paul is leading DMS group where his expertise has blossomed through acquirement of  several companies all highly focused on human health, particularly personalized medicine.